September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Genetic and pharmacological inhibition of ER stress-induced ATF4/CHOP prodeath pathway prevents myocilin misfolding and rescues mouse models of glaucoma
Author Affiliations & Notes
  • Ramesh Babu Kasetti
    Cell Biology & Immunology, North Texas Eye Research Institute, University of North Texas HSC, Fortworth, Texas, United States
  • Tien Phan
    Cell Biology & Immunology, North Texas Eye Research Institute, University of North Texas HSC, Fortworth, Texas, United States
  • Charles C Searby
    Department of Pediatrics, Division of Medical Genetics, Wynn Institute for Vision Research, University of Iowa Carver College of Medicine, Iowa , Iowa, United States
  • Val Sheffield
    Department of Pediatrics, Division of Medical Genetics, Wynn Institute for Vision Research, University of Iowa Carver College of Medicine, Iowa , Iowa, United States
  • Gulab Zode
    Department of Pediatrics, Division of Medical Genetics, Wynn Institute for Vision Research, University of Iowa Carver College of Medicine, Iowa , Iowa, United States
  • Footnotes
    Commercial Relationships   Ramesh Kasetti, None; Tien Phan, None; Charles Searby, None; Val Sheffield, None; Gulab Zode, None
  • Footnotes
    Support  NH Grant EY022077
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5634. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Ramesh Babu Kasetti, Tien Phan, Charles C Searby, Val Sheffield, Gulab Zode; Genetic and pharmacological inhibition of ER stress-induced ATF4/CHOP prodeath pathway prevents myocilin misfolding and rescues mouse models of glaucoma. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5634.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We recently demonstrated that ER stress-induced pro-death markers including ATF4 and CHOP are significantly increased in human post-mortem glaucomatous trabecular meshwork (TM) tissues. The purpose of this study was to further explore the role of ATF4/CHOP in myocilin misfolding in TM and IOP elevation.

Methods : ATF4 and CHOP levels were analyzed in TM of Tg-MYOCY437H and dexamethasone (Dex)-treated mice by Western blotting (n=3). Conscious IOP was monitored by rebound tonometer in C57 mice injected intravitreally with Ad5 Null or ATF4 virus. IOP was measured in Chop-/-Tg-MYOCY437H mice and compared to Chop+/+Tg-MYOCY437H and WT mice. The effects of CRISPR-Cas9 mediated knockdown of ATF4/CHOP on myocilin accumulation was studied TM-5 cells expressing mutant myocilin. Myocilin accumulation and ER stress was examined in TM cells treated with pharmacological inhibitor of ATF4/CHOP pathway, ISRIB (100 and 200nM) for 48 hours. Furthermore, ocular hypertensive Tg-MYOCY437H mice were treated with an intravitreal injection of ISRIB (2ul, 2mM) and IOP was measured 4 days post-injections.

Results : Western blot analysis demonstrated increased ATF4 and CHOP levels in the iridocorneal angle tissues of Tg-MYOCY437H and Dex-treated mice. Forced expression of Ad5.ATF4 lead to significant IOP elevation in WT mice (16mmHg in null vs 23mmHg in Ad5.ATF4-injected mice; p<0.0001, n=8). Chop+/+Tg-MYOCY437H mice (22mmHg, n=16) significantly elevated IOP compared to WT Chop+/+ littermates (16.5mmHg, n=4) while Chop-/-Tg-MYOCY437H mice (19mmHg, n=8) did not elevate IOP compared to Chop-/- littermates (18mmHg, n=6) indicating that deletion of Chop rescued ocular hypertension in Tg-MYOCY437H mice. In addition, Cas9 targeting ATF4 or CHOP dramatically reduced ATF-4 and CHOP level and also reduced myocilin accumulation and ER stress in TM-5 cells. Treatment of TM cells with ISRIB (100nM) dramatically reduced myocilin accumulation and also prevented ER stress. Pharmacological inhibition of ATF4/CHOP pathway via ISRIB (2mM) significantly reduced elevated IOP in Tg-MYOCY437H mice (14.5mmHg in vehicle vs 10mmHg in ISRIB treated Tg-MYOCY437H mice, p<0.0008, n=5).

Conclusions : These studies indicate that genetic or pharmacological inhibition of ATF4/CHOP pathway may provide novel treatment for glaucoma.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×